Xenon Pharmaceuticals (XENE) Liabilities and Shareholders Equity (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $1.4 billion in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $1.4 billion, up 86.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.3 billion (up 1.25% YoY), and the FY2025 annual result was $633.2 million, down 20.67% from the prior year.
• Liabilities and Shareholders Equity grew to $1.4 billion in Q1 2026 per XENE's latest filing, from $633.2 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $1.4 billion in Q1 2026 and troughed at $558.1 million in Q1 2022.
• A 5-year average of $789.3 million and a median of $754.1 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity soared 193.9% in 2022, then dropped 27.28% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $754.1 million in 2022, then increased by 27.93% to $964.8 million in 2023, then declined by 17.27% to $798.1 million in 2024, then fell by 20.67% to $633.2 million in 2025, then soared by 119.03% to $1.4 billion in 2026.
• Business Quant data shows XENE's Liabilities and Shareholders Equity at $1.4 billion in Q1 2026, $633.2 million in Q4 2025, and $607.8 million in Q3 2025.